BACKGROUND: Familial glucocorticoid deficiency (FGD) is an autosomal recessive disorder characterized by isolated glucocorticoid deficiency. Mutations in the ACTH receptor [melanocortin 2 receptor (MC2R)] or the MC2R accessory protein (MRAP) cause FGD types 1 and 2, respectively. Typically, type 2 patients present early (median age, 0.1 yr), and no patient reported to date has presented after 1.6 yr. AIM: The aim of this study was to investigate the cause of disease in two families with late-onset FGD. PATIENTS: The proband in family 1 was diagnosed at age 4 yr. Family review revealed two older siblings with undiagnosed FGD. One sibling was well, whereas the second had cerebral palsy secondary to hypoglycemic seizures. The proband in family 2 was diagnosed at age 18 yr with symptoms of fatigue, weight loss, and depression. METHODS: The coding exons of MC2R and MRAP were sequenced. ACTH dose-response curves were generated for MC2R when transfected with wild-type or mutant MRAP constructs using HEK293 cells. MC2R trafficking with both mutant MRAPs was investigated using immunocytochemistry. RESULTS: MRAP gene analysis identified two novel homozygous missense mutations, c.175T>G (pY59D) in family 1 and c.76T>C (p.V26A) in family 2. In vitro analysis showed that the Y59D mutant had significant impairment of cAMP generation, and both mutants caused a shift in the dose-response curve to the right when compared to wild type. Immunocytochemistry showed normal trafficking of MC2R when transfected with both mutant MRAPs, indicating a probable signaling defect. CONCLUSION: These results indicate that missense MRAP mutations present with a variable phenotype of ACTH resistance and can present late in life.
BACKGROUND:Familial glucocorticoid deficiency (FGD) is an autosomal recessive disorder characterized by isolated glucocorticoid deficiency. Mutations in the ACTH receptor [melanocortin 2 receptor (MC2R)] or the MC2R accessory protein (MRAP) cause FGD types 1 and 2, respectively. Typically, type 2 patients present early (median age, 0.1 yr), and no patient reported to date has presented after 1.6 yr. AIM: The aim of this study was to investigate the cause of disease in two families with late-onset FGD. PATIENTS: The proband in family 1 was diagnosed at age 4 yr. Family review revealed two older siblings with undiagnosed FGD. One sibling was well, whereas the second had cerebral palsy secondary to hypoglycemic seizures. The proband in family 2 was diagnosed at age 18 yr with symptoms of fatigue, weight loss, and depression. METHODS: The coding exons of MC2R and MRAP were sequenced. ACTH dose-response curves were generated for MC2R when transfected with wild-type or mutant MRAP constructs using HEK293 cells. MC2R trafficking with both mutant MRAPs was investigated using immunocytochemistry. RESULTS:MRAP gene analysis identified two novel homozygous missense mutations, c.175T>G (pY59D) in family 1 and c.76T>C (p.V26A) in family 2. In vitro analysis showed that the Y59D mutant had significant impairment of cAMP generation, and both mutants caused a shift in the dose-response curve to the right when compared to wild type. Immunocytochemistry showed normal trafficking of MC2R when transfected with both mutant MRAPs, indicating a probable signaling defect. CONCLUSION: These results indicate that missense MRAP mutations present with a variable phenotype of ACTH resistance and can present late in life.
Authors: Abdelhadi M Habeb; Claire R Hughes; Rida Al-Arabi; Ali Al-Muhamadi; Adrian J L Clark; L A Metherell Journal: Eur J Pediatr Date: 2013-05-26 Impact factor: 3.183
Authors: Shwetha Ramachandrappa; Rebecca J Gorrigan; Adrian J L Clark; Li F Chan Journal: Front Endocrinol (Lausanne) Date: 2013-02-08 Impact factor: 5.555
Authors: Li F Chan; Daniel C Campbell; Tatiana V Novoselova; Adrian J L Clark; Louise A Metherell Journal: Front Endocrinol (Lausanne) Date: 2015-08-05 Impact factor: 5.555